Simulations Plus Partners with Bayer AG to Develop New Cheminformatics Capabilities in ADMET Predictor
Summary
With the drugmaker’s input, Simulations Plus will develop improved structure and tautomer handling capabilities that will support data integrity across the different Bayer discovery platforms. “We have partnered with Bayer on several scientific projects in the past and are pleased to announce this new collaboration supporting machine learning in drug discovery activities,” said David Miller, Director of ADMET Cheminformatics at Simulations Plus. The outcome from this collaboration will do just that and lead to improved efficiencies as compound libraries are virtually screened using our top-rated ADMET models.” John DiBella, Lancaster division president for Simulations Plus, added: “This agreement is a prime example of a funding mechanism targeted to the specific advancement of customized software solutions essential to a client. In the end, these enhancements will be part of a fully supported platform and benefit our entire user community.” About Simulations Plus, Inc. Simulations Plus, Inc. is a premier developer of drug discovery/development software and a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions and quantitative systems pharmacology models for drug-induced liver injury, drug-induced kidney injury, and nonalcoholic fatty liver disease. Our software is used to conduct drug research by major pharmaceutical, biotechnology, chemical, consumer goods companies, and regulatory agencies worldwide.
Classifications
AskAI Classifications
LabelsLinked Companies
